Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis
Authors:
- Eytan WineEWEytan Wine
- David R. MackDMDavid R. Mack
- Jeffrey HyamsJHJeffrey Hyams
- Anthony R. OtleyAOAnthony R. Otley
- James MarkowitzJMJames Markowitz
- Wallace V. CrandallWCWallace V. Crandall
- Neal LeleikoNLNeal Leleiko
- Aleixo M. MuiseAMAleixo M. Muise
- Anne M. GriffithsAGAnne M. Griffiths
- Dan TurnerDTDan Turner
- 1 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 7 (11) , 916-922
Abstract
Approximately one third of patients with acute severe ulcerative colitis (ASC) will fail intravenous corticosteroids (IVCS). Predicting response to IVCS to initiate early salvage therapy remains challenging. The aim of this study was to evaluate the role of serum inflammatory cytokines in ASC and determine their predictive utility with IVCS treatment failure. This preplanned ancillary study, part of the prospective multicenter OSCI study, evaluated pediatric ASC in North America. Serum samples were obtained from 79 children admitted for ASC on the third day of IVCS treatment. Twenty-three (29%) patients required second-line therapy. ELISA-based cytokine arrays were used [TNF-α, IFN-γ, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, and IL-17], selected based on a systematic literature search. In univariate analysis, only IL-6 was significantly different between responders and non-responders (P=0.003). The risk for IVCS failure increased by 40% per each pg/mL increase in IL-6 level. Factor analysis found IL-6 to be associated with IL-17, suggesting involvement of the T-helper (TH)17 pathway. In a multivariate analysis, disease activity [judged by the Pediatric UC Activity Index (PUCAI)] assumed all the association with the treatment outcome while IL-6 was no longer significant (P=0.32; PUCAI score P<0.001). While IL-6 strongly predicted IVCS failure, it likely reflects disease activity and not direct interference with corticosteroid pathway. Nonetheless, IL-6 levels may have a role in predicting IVCS response in severe pediatric UC for treatment decision-making or potentially in medical intervention by virtue of anti-IL-6 antibodies in severe UC.Keywords
This publication has 39 references indexed in Scilit:
- Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative ColitisClinical Gastroenterology and Hepatology, 2012
- Hck Tyrosine Kinase Regulates TLR4-Induced TNF and IL-6 Production via AP-1The Journal of Immunology, 2011
- Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkersGut, 2010
- Glucocorticoid-mediated Inhibition of Lck Modulates the Pattern of T Cell Receptor-induced Calcium Signals by Down-regulating Inositol 1,4,5-Trisphosphate ReceptorsJournal of Biological Chemistry, 2009
- Effect of Budesonide and Formoterol on Il-6 and Il-8 Release from Primary Bronchial Epithelial CellsJournal of Asthma, 2008
- Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinasesOncogene, 2007
- Interleukin 6: from bench to bedsideNature Clinical Practice Rheumatology, 2006
- Glucocorticoids cause rapid dissociation of a T‐cell‐receptor‐associated protein complex containing LCK and FYNEMBO Reports, 2006
- Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcomeEuropean Journal of Gastroenterology & Hepatology, 2005
- Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphismsMediators of Inflammation, 2004